Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 1.00 |
| ▸ | LCK | P06239 | 14/20 | 1.00 |
| ▸ | TEK | Q02763 | 13/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | EGFR | P00533 | 5/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | CSK | P41240 | 2/20 | 1.00 |
| ▸ | BTK | Q06187 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | RGS12 | O14924 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378454 | 1.00 | SRC (1.00) | SRCLCKTEKKDREGFR | |
| SCHEMBL23834505 | 0.99 | SRC (0.98) | SRCLCKTEKKDREGFR | |
| SCHEMBL24458610 | 0.98 | SRC (0.96) | SRCLCKTEKKDREGFR | |
| SCHEMBL16752438 | 0.91 | SRC (0.84) | SRCLCKTEKKDREGFR | |
| SCHEMBL6458490 | 0.91 | LCK (0.98) | SRCLCKTEKKDREGFR | |
| SCHEMBL6458486 | 0.91 | LCK (0.98) | SRCLCKTEKKDREGFR | |
| SCHEMBL6460765 | 0.91 | LCK (0.98) | SRCLCKTEKKDREGFR | |
| SCHEMBL7004447 | 0.90 | LCK (1.00) | SRCLCKTEKKDREGFR | |
| SCHEMBL6466052 | 0.90 | LCK (1.00) | SRCLCKTEKKDREGFR | |
| SCHEMBL6465227 | 0.90 | SRC (1.00) | SRCLCKTEKKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025261943-A1 | ANTI-CANCER COMBINATIONS COMPRISING MOSPERAFENIB AND FOLFOX OR FOLFIRI | F. HOFFMANN-LA ROCHE AG (CH) | 2025-12-26 | — | — | WO | disclosed |
| EP-4634172-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | F. Hoffmann-La Roche AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| EP-4426305-A1 | NOVEL USE OF QUINAZOLINONE COMPOUND FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-09-11 | — | — | EP | disclosed |
| CN-114026073-B | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118369318-A | Crystalline forms of N- (2-chloro-3- ((5-chloro-3-methyl-4-oxo-3, 4-dihydroquinazolin-6-yl) amino) -4-fluorophenyl) -3-fluoroazetidine-1-sulfonamide | 阿雷生物药品公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024126660-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-20 | — | — | WO | disclosed |
| CN-118201615-A | New use of quinazolinone compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117813094-A | Combinations of specific BRAF inhibitors (paradox inhibitors) and PD-1 axis binding antagonists for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117642166-A | Combination therapy for cancer treatment | 中外制药株式会社 | 2024-03-01 | — | — | CN | disclosed |
| EP-4320244-A1 | MEANS AND METHODS FOR ENHANCING RECEPTOR-TARGETED GENE TRANSFER | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2024-02-14 | — | — | EP | disclosed |
| CN-117120620-A | Means and methods for enhancing receptor-targeted gene transfer | 德国癌症研究公共权益基金会 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023078881-A1 | NOVEL USE OF QUINAZOLINONE COMPOUND FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-11 | — | — | WO | disclosed |
| EP-4161907-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINON COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array BioPharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022214588-A1 | MEANS AND METHODS FOR ENHANCING RECEPTOR-TARGETED GENE TRANSFER | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2022-10-13 | — | — | WO | disclosed |